Literature DB >> 32239440

Variable Expression of S100 Protein in Sinonasal Malignant Mucosal Melanoma: A Potential Diagnostic Pitfall.

Xiang Xu1, Doreen Palsgrove1, Elizabeth Kurian1, Shirley Yan1, Bahram R Oliai2, Justin A Bishop3.   

Abstract

Sinonasal malignant mucosal melanoma (SNM) is a rare, aggressive malignancy. The diagnosis of SNM is often quite challenging due to anatomical limitations, frequent lack of pigmentation, variable histologic appearances, and aberrant differentiation (e.g., positivity for cytokeratin, desmin, or neuroendocrine markers). S100 protein is routinely used as a standard screening marker for SNM, but it may lack optimal sensitivity. Our objective was to study the extent of immunohistochemical expression of S100 protein in SNM, and determine its diagnostic value by comparing it to a newer melanoma marker, SOX10. Twenty-three cases of sinonasal MMM were retrieved from the archival files of the Department of Pathology at UT Southwestern Medical Center. The patients included 14 men and 9 women, and ranged from 36 to 90 years (mean 64.9 years). Sections from blocks of formalin-fixed, paraffin-embedded tissue were used for immunohistochemical analysis with S100 protein and SOX10. The extent and intensity of immunostaining was recorded, and H-score was calculated. For a subset of negative or focally positive cases, S100 protein was repeated at a high-volume reference laboratory. S100 protein immunoexpression was quite variable in the SNM cases, with H-scores ranging from 0 to 300 (mean 123). While 11 of 23 cases exhibited strong and diffuse staining (H-score > 100) as expected for melanoma, 7 were weak and/or focal (H-score 1-100), and 5 were completely S100 protein-negative. For 10 cases, the negative or focal results were confirmed by reference laboratory staining. In contrast, all 23 SNM cases were diffusely and strongly positive for SOX10 (H-scores 210-300, mean 296). Our study demonstrated that S100 protein immunoexpression is extremely variable in SNM. Weak or even absent S100 protein staining is not uncommon in SNM, and should not dissuade pathologists from that diagnosis. Our data demonstrates that S100 protein is insufficiently sensitive to be used as a screening marker for SNM, but that SOX10 is consistently and robustly positive, and should therefore replace S100 protein for that purpose. Indeed, for any high-grade sinonasal tumor, pathologists must have a low threshold for utilizing additional markers to exclude the possibility of SNM.

Entities:  

Keywords:  Malignant mucosal melanoma; S100 protein; SOX10; Sinonasal tract; Small round blue cell tumor

Year:  2020        PMID: 32239440      PMCID: PMC7669918          DOI: 10.1007/s12105-020-01158-8

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  27 in total

1.  Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.

Authors:  Melike Pekmezci; Areli K Cuevas-Ocampo; Arie Perry; Andrew E Horvai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Vaginal melanoma: a clinicopathologic and immunohistochemical study of 26 cases.

Authors:  Deepali Gupta; Anais Malpica; Michael T Deavers; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2002-11       Impact factor: 6.394

3.  Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population.

Authors:  Hong Gang Liu; Max Xiangtian Kong; Qian Yao; Shu Yi Wang; Robert Shibata; Herman Yee; Frank Martiniuk; Beverly Y Wang
Journal:  Head Neck Pathol       Date:  2012-06-27

Review 4.  The small round blue cell tumors of the sinonasal area.

Authors:  Julia A Bridge; Joslin M Bowen; Russell B Smith
Journal:  Head Neck Pathol       Date:  2010-01-26

5.  Primary mucosal melanoma of the sinonasal tract: a clinicopathologic and immunohistochemical study of thirty-two cases.

Authors:  Mark C Mochel; Lyn M Duncan; Adriano Piris; Stefan Kraft
Journal:  Head Neck Pathol       Date:  2014-10-08

6.  Sinonasal tract and nasopharyngeal melanomas: a clinicopathologic study of 115 cases with a proposed staging system.

Authors:  Lester D R Thompson; Jacqueline A Wieneke; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2003-05       Impact factor: 6.394

7.  Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response.

Authors:  Robert M Samstein; Richard D Carvajal; Michael A Postow; Margaret K Callahan; Alexander N Shoushtari; Snehal G Patel; Nancy Y Lee; Christopher A Barker
Journal:  Head Neck       Date:  2016-04-04       Impact factor: 3.147

Review 8.  An Update on Sinonasal Round Cell Undifferentiated Tumors.

Authors:  Alessandro Franchi
Journal:  Head Neck Pathol       Date:  2016-02-01

Review 9.  Newly Described Tumor Entities in Sinonasal Tract Pathology.

Authors:  Justin A Bishop
Journal:  Head Neck Pathol       Date:  2016-02-01

10.  Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics.

Authors:  Inga-Marie Schaefer; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-11-20       Impact factor: 7.842

View more
  4 in total

Review 1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: The Neck and Lymph Nodes, Metastasis, and Melanocytic Tumors.

Authors:  Juan C Hernandez-Prera
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 2.  Epstein-Barr Virus-Associated Smooth Muscle Tumors of Larynx: A Clinicopathologic Study and Comprehensive Literature Review of 12 Cases.

Authors:  Rumeal D Whaley; Lester D R Thompson
Journal:  Head Neck Pathol       Date:  2021-04-23

Review 3.  RAGE Signaling in Melanoma Tumors.

Authors:  Olamide T Olaoba; Sultan Kadasah; Stefan W Vetter; Estelle Leclerc
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

4.  Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.

Authors:  Yan Wu; Yumei Lai; Miao Zhang; Zhongwu Li
Journal:  Diagn Pathol       Date:  2021-08-28       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.